Elicio Therapeutics, Inc. Payments of Financing Costs
Elicio Therapeutics, Inc. (ELTX) reported Payments of Financing Costs of $228.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2023-05-10
- Elicio Therapeutics, Inc. payments of financing costs for the quarter ending 2023-03-31 was $228.00K.
- Elicio Therapeutics, Inc. payments of financing costs for the quarter ending 2022-03-31 was $0.00.
| Period end | Payments of Financing Costs 3 month |
|---|---|
| 2023-03-31 | $228.00K 10-Q · filed 2023-05-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |